Open Orphan PLC's (LON:ORPH) Cathal Friel says they're targeting operational profitability by the third quarter of the year following its merger with hVIVO. Speaking to Proactive following the release of its full-year results Friel says they're seeing unprecedented growth opportunities as pharma focuses funding on Covid-19 and respiratory diseases.
Open Orphan reports unprecedented growth opportunities and strong pipeline to build revenues
Quick facts: Open Orphan PLC
Price: 15.25 GBX
Market Cap: £101.51 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE